Genomic Updates To Drug Labeling Could Result From Medco/FDA Partnership
Executive Summary
FDA could use results from a new research collaboration with Medco to update existing drug labeling with genomic information. Announced by Medco on Aug. 18, the project calls for the pharmacy benefit management company to draw from its pharmacy claims data base and its own physician and member surveys to produce a series of reports on the impact of genetic testing on drug efficacy and safety
You may also be interested in...
Warfarin Sensitivity Testing: Medco/Mayo Study Results Due Early 2010
Medco is planning to release an observational study in early 2010 on the benefits of pharmacogenomic testing in warfarin dosing. It hopes the results will increase payer acceptance of the approach to treatment
Warfarin Sensitivity Testing: Medco/Mayo Study Results Due Early 2010
Medco is planning to release an observational study in early 2010 on the benefits of pharmacogenomic testing in warfarin dosing. It hopes the results will increase payer acceptance of the approach to treatment
Medco Personalized Medicine Research Shows “Real World” Promise – Frueh
Medco's research can advance the cause of personalized medicine by proving its benefits in a "real world" setting, according to Felix Frueh, the firm's new VP of research and development for personalized medicine